Indeed, with the exception of the potentiator, Kalydeco (ivacaftor, VX770), all the FDA- and EMA-approved CFTR drugs targeting the underlying genetic cause of CF currently on the market consist of a combination of the potentiator ivacaftor (VX770) and one or two correctors: Orkambi, made up of VX770 and the corrector lumacaftor (VX809); Symdeko, a combination of VX770 and the corrector tezacaftor (VX661); and the latest Trikafta/Kaftrio, which combines the VX770 with the correctors tezacaftor (VX661) and elexacaftor (VX445) (see Figure 1) [29,30,31,32]. The gene discussed is CFTR; the disease is cystic fibrosis.